CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 143 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $9,400,000 | -30.4% | 622,548 | -14.7% | 0.38% | -22.3% |
| Q3 2018 | $13,504,000 | -19.1% | 729,948 | 0.0% | 0.48% | -17.4% |
| Q2 2018 | $16,687,000 | -22.1% | 729,948 | -3.1% | 0.59% | -21.1% |
| Q1 2018 | $21,432,000 | +34.8% | 753,322 | 0.0% | 0.74% | +18.7% |
| Q4 2017 | $15,903,000 | +15.6% | 753,322 | -0.5% | 0.63% | +1.1% |
| Q3 2017 | $13,751,000 | +17.2% | 756,822 | 0.0% | 0.62% | -1.1% |
| Q2 2017 | $11,731,000 | -28.0% | 756,822 | -19.8% | 0.63% | -0.3% |
| Q1 2017 | $16,293,000 | +57.1% | 943,433 | 0.0% | 0.63% | +47.1% |
| Q4 2016 | $10,368,000 | -29.9% | 943,433 | 0.0% | 0.43% | -37.9% |
| Q3 2016 | $14,793,000 | +53.5% | 943,433 | 0.0% | 0.69% | +81.5% |
| Q2 2016 | $9,637,000 | -20.8% | 943,433 | 0.0% | 0.38% | -26.8% |
| Q1 2016 | $12,170,000 | -38.4% | 943,433 | -0.3% | 0.52% | -35.2% |
| Q4 2015 | $19,743,000 | – | 946,022 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,803,700 | $25,130,000 | 0.91% |
| Altium Capital Management LP | 663,800 | $2,874,000 | 0.79% |
| Rubric Capital Management LP | 2,406,449 | $10,420,000 | 0.49% |
| RTW INVESTMENTS, LP | 6,029,700 | $26,109,000 | 0.38% |
| Orbimed Advisors | 3,214,509 | $13,919,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 152,345 | $660,000 | 0.13% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 980,085 | $4,244,000 | 0.12% |
| Point72 Asset Management, L.P. | 6,303,025 | $27,292,000 | 0.11% |
| Sender Co & Partners, Inc. | 40,720 | $176,000 | 0.09% |
| Manteio Capital LLC | 15,067 | $65,000 | 0.08% |